drugset

drugset / Trial / NCT00755027

Rasagiline and Apathy in Parkinson's Disease

NCT00755027 ↗

Phase 4 Completed 40 enrolled Sant Pau Research Institute

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether rasagiline is effective in the treatment of apathy in patients with Parkinson's disease.

Timeline

Start: 2008-09
Primary completion: 2014-06
Completion: 2014-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rasagiline	Small molecule	1 mg	Oral

Indications